Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Haematology"
DOI: 10.1111/bjh.15819
Abstract: Myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN) and chronic myelomonocytic leukaemia (CMML) can progress to secondary acute myeloid leukaemia (sAML). We compared the outcome of 4214 sAML patients who received allogeneic haematopoietic stem cell transplantation (allo‐HSCT)… read more here.
Keywords: stem cell; leukaemia; saml; disease ... See more keywords
Risk and outcome of acute myeloid leukaemia among survivors of primary diffuse large B-cell lymphoma: a retrospective observational study based on SEER database
Sign Up to like & getrecommendations! Published in 2022 at "BMJ Open"
DOI: 10.1136/bmjopen-2022-061699
Abstract: Objectives Survivors of diffuse large B-cell lymphoma (DLBCL) are at an increased risk of developing second primary malignancies. However, the risk of secondary acute myeloid leukaemia (sAML) has not been previously described in detail, and… read more here.
Keywords: database; seer database; acute myeloid; saml ... See more keywords
Inferior Outcome of Allogeneic Stem Cell Transplantation in First Complete Remission for Secondary AML As Compared to De Novo Disease: Results from a Retrospective, Registry-Based Analysis on Behalf of the Acute Leukemia Working Party of the EBMT
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-113779
Abstract: Background: Acute myeloid leukemia (AML) secondary to haematological neoplasia or other malignant diseases, defined as secondary AML (sAML), is thought to have an inferior prognosis as compared with de novo AML. However, when corrected for… read more here.
Keywords: cell; analysis; saml; novo aml ... See more keywords
Pre-Clinical Efficacy of Co-Targeting GFI1/KDM1A and BRD4 or JAK1/2 Against AML and Post-MPN Secondary AML Blast Progenitor Cells
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-140212
Abstract: Transcriptional regulators (TFs) involved in cell-growth, differentiation and survival of AML stem/progenitor cells (LSCs) include RUNX1, PU.1, CEBPα, c-Myb and c-Myc. LSD1 (KDM1A) is an FAD-dependent amine-oxidase that demethylates mono and dimethyl histone H3 lysine… read more here.
Keywords: research; honoraria research; saml; differentiation ... See more keywords
Optimal Therapy for Secondary Acute Myeloid Leukemia after Prior Hypomethylating Therapy
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-206258
Abstract: Background: Patients (pts) with secondary acute myeloid leukemia (sAML) emerging from myelodysplastic syndrome (AML-MR) with extensive prior hypomethylating agent (HMA) exposure remain a high unmet need with significantly worse survival (4.2 months) and complete remission… read more here.
Keywords: therapy; ven based; secondary acute; saml ... See more keywords
Comparable survival outcomes after myeloablative allogeneic stem cell transplantation in secondary and de novo Acute Myeloid Leukemia in first complete remission: A propensity Score–Matched study
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-7741
Abstract: Secondary acute myeloid leukemia (sAML) is a distinct subtype of AML characterized by poor prognosis, arising either from a pre-existing hematologic disorder—primarily myelodysplastic syndromes (MDS) or myeloproliferative neoplasms (MPNs)—or as a consequence of prior cytotoxic… read more here.
Keywords: survival; saml; cell; gvhd ... See more keywords